A Pilot Trial Using BR55 Ultrasound Contrast Agent in the Assessment of Prostate Cancer

Inclusion Criteria: * Male, age between 50-70 years old * Increased Prostate-Specific Antigen (PSA) level \>4 ng/mL * Known prostate cancer * Scheduled for prostatectomy not earlier than 3 days and not later than 30 days following BR55 administration (with the exception of training cases where this requirement is not applicable) * Provided written informed consent and willing to comply with protocol requirements Exclusion Criteria: * Documented acute prostatitis or urinary tract infections * Known to suffer from stable angina pectoris and/or proven coronary disease, or have symptoms suspicious of coronary disease * History of any clinically unstable cardiac condition including class III/IV cardiac failure or right-to left shunts * Severe cardiac rhythm disorders within the last 7 days * Severe pulmonary hypertension or uncontrolled systemic hypertension or respiratory distress syndrome * Received a prostate biopsy procedure within 30 days before admission into the study * Determined by investigator to be clinically unsuitable for the study * Participated in a concurrent clinical trial or has participated in another clinical trial with an investigational compound within the past 30 days